FULC
Fulcrum Therapeutics, Inc.
There isn't enough reported data to score FULC yet.
FULC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
FULC's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
FULC PE Valuation
FULC has no meaningful PE right now: it lost money over the past year.
FULC Forward outlook
There aren't enough analyst estimates for FULC to show an outlook.
FULC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.04 | +$0.08 |
| Q2 2026 | -$1.21 | -$0.05 |
| Q1 2026 | -$1.15 | -$1.14 |
| Q4 2025 | -$1.18 | -$1.02 |
FULC is still losing money, but far less than before: $1.04 per share over the past year, against $2.44 at its worst in late 2022.
FULC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $80M | +8991% |
| Q4 2023 | $871K | +27% |
| Q3 2023 | $759K | -36% |
| Q2 2023 | $880K | -53% |
| Q1 2023 | $295K | -89% |
| Q4 2022 | $685K | -86% |
| Q3 2022 | $1.2M | -76% |
| Q2 2022 | $1.9M | -57% |
FULC's revenue has slid since its 2024 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2024 | 66% | +3167 points |
| Q4 2023 | -3214% | +870 points |
| Q3 2023 | -3615% | -1557 points |
| Q2 2023 | -3101% | -1282 points |
| Q1 2023 | -9471% | -8468 points |
| Q4 2022 | -4084% | -3618 points |
| Q3 2022 | -2059% | -1638 points |
| Q2 2022 | -1819% | -1370 points |
FULC's operating margin was 66% last quarter, up 9537 points from the same quarter a year ago, near the top of its range since 2020.
FULC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$13.4M | +$898K |
| Q2 2026 | -$16.1M | -$2.3M |
| Q1 2026 | -$18.8M | -$3.5M |
| Q4 2025 | -$17M | +$35K |
| Q3 2025 | -$14.3M | +$4.8M |
| Q2 2025 | -$13.9M | -124% |
| Q1 2025 | -$15.3M | +$10.1M |
| Q4 2024 | -$17M | +$6.2M |
FULC has burned cash in almost every quarter: −$65M over the past year, against −$60M the year before.
FULC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +52K shares |
| 1 year | +22% | +13.8M shares |
FULC has 76M diluted shares, up 22% from a year ago.
FULC Net Leverage
FULC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
FULC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.7 | Neutral |
| Stochastic | 36.6 | Neutral |
FULC's weekly RSI is 36 (neutral) and its Stochastic is 37 (neutral).
FULC PE vs Healthcare Sector
FULC has no meaningful PE right now: it lost money over the past year.
FULC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.70 | 0.5% below |
| 20 week MA | $3.73 | 1.3% below |
| 50 week MA | $6.46 | 43% below |
| 100 week MA | $6.30 | 42% below |
| 200 week MA | $6.10 | 40% below |
FULC is in a downtrend: it's below all five of its weekly moving averages, and 40% below its 200-week average.
FULC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.0 | $12.5 | -26% |
| 2021 | $12.5 | $18.1 | +45% |
| 2022 | $18.1 | $6.25 | -65% |
| 2023 | $6.25 | $6.75 | +8% |
| 2024 | $6.75 | $4.79 | -29% |
| 2025 | $4.79 | $11.6 | +142% |
| 2026 YTD | $11.6 | $3.68 | -68% |
FULC's yearly returns have swung widely, from +142% in 2025 to −65% in 2022. It's down 68% so far in 2026.